Related Experiment Video
Updated: Jun 18, 2026
09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Bidirectional relationship between metabolic and thrombotic disease mechanisms
Angelica T Jameson1, Woosuk S Hur
1Department of Pathology and Laboratory Medicine, and Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Current Opinion in Hematology
|June 17, 2026
Summary
Metabolic diseases increase thrombosis risk, partly due to suppressed fibrinolysis from elevated PAI-1. Novel therapies targeting PAI-1 and understanding factors like urokinase and FXIIIA are crucial for managing these interconnected conditions.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Hematology
Background:
- Metabolic diseases (obesity, MASLD, diabetes) are linked to higher thrombotic risks.
- Hemostatic system components influence metabolic disease development, indicating a bidirectional relationship.
Purpose of the Study:
- To review recent advances in how metabolic pathologies drive thrombosis.
- To update on how hemostatic system components modulate metabolic diseases.
Main Methods:
- Literature review of recent studies on metabolic diseases and thrombosis.
- Analysis of mechanisms linking hemostasis and metabolic dysfunction.
Main Results:
- Metabolic pathologies suppress fibrinolytic activity, primarily via elevated PAI-1.
- Urokinase plasminogen activator and Factor XIIIA are implicated in metabolic pathology development.
- Weight loss therapies show potential in reducing metabolic dysfunction-associated thrombosis.
Conclusions:
- Targeting PAI-1 is a promising strategy for attenuating thrombotic risks.
- Urokinase and FXIIIA are identified as promoters of metabolic dysfunction, especially MASLD.
- Further research is needed on the cardiovascular impact of GLP-1 receptor agonists in obesity.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...